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Background: The post-polio syndrome occurs in people who previously have had poliomyelitis. After the initial
recovery, new or increasing neurologic symptoms occur. Inflammation and dyslipidaemia may play an important
role in the development of atherosclerotic complications, for example myocardial infarction and angina pectoris.
Previous studies on cardiovascular risk factors in the post-polio syndrome have found a higher prevalence of
hypertension, ischemic heart disease, hyperlipidaemia, and stroke in these patients. The present study was undertaken
in order to evaluate whether post-polio patients have elevated lipid values, and if blood lipid abnormalities could be
correlated to signs of inflammation.
Methods: Cross-sectional study of 89 consecutive post-polio patients, (53 women, mean age 65 years) from the
Post-Polio Outpatient Clinic, Danderyd University Hospital, Stockholm, Sweden. The lipid profiles of post-polio patients
were compared to age and sex matched reference values from two earlier studies. Statistical analyses were performed
by the Student’s t-test, and linear regression analyses were assessed by Pearson’s correlation coefficient.
Results: Mean total cholesterol levels (5.7 mmol/L) were low or normal in post-polio patients, whereas low density
lipoprotein levels (3.6 mmol/L) were normal, and high density lipoprotein (1.5 mmol/L) and triglycerides (1.4 mmol/L)
lower than reference values. The prevalence of diabetes (7%), hypertension (38%), concomitant cardiovascular disease,
(including angina pectoris, myocardial infarction, heart failure, atrial fibrillation and stroke) (7%), and calculated 10
year risk of coronary heart disease according to Framingham risk score algorithm (8%) was not increased in
post-polio patients.
Conclusions: Compared to reference populations, post-polio patients in Sweden appear to have low or normal total
cholesterol and low density lipoprotein levels, whereas high density lipoprotein and triglyceride levels are low. Hence, a
possible persisting inflammatory process in post-polio syndrome does not seem to be associated with increased lipids
and an increased risk for coronary heart disease events.
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The post-polio syndrome (PPS) is a condition occurring
in people who previously have had poliomyelitis [1].
After an initial recovery, new or increasing symptoms
occur, following a stable period of at least 15 years. Symp-
toms include muscle atrophy and weakness, muscle and
joint pain, sensitivity to cold, fatigue, and dysphagia [1].* Correspondence: eva.melin@ki.se
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unless otherwise stated.Due to their disability, PPS patients are less mobile than
the normal population [2]. Decreased mobility could lead
to weight gain and difficulties in physical exercise and
maintenance of fitness. It has been assumed that this
could have negative effects on the general health of PPS
patients and increase the risk of cardiovascular disease, as
seen in other disorders with muscle weakness, e.g. spinal
cord injury [3]. Kang et al. [4] reported a higher preva-
lence of hypertension and ischemic heart disease in polio
survivors in China. Dyslipidaemia was also described as
comorbidity, which is in accordance with older studies inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of the PPS patients included in
the study
Female Male All
n 53 36 89
Age, years 66 (8) 64 (9) 65 (9)
Systolic blood pressure, mm Hg 139 (15) 139 (15) 139 (15)
HbA1c, % 4.7 (0.6) 4.8 (0.8) 4.7 (0.7)
Creatinine, μmol/L 56 (11) 66 (18) 60 (15)
C-reactive protein, mg/L 3.2 (2.3) 3.3 (2.2) 3.2 (2.2)
Erythrocyte sedimentation rate, mm 13.8 (8.8) 8.4 (5.5) 11.7 (8.1)
Leukocyte count, 109/L 6.2 (1.6) 6.3 (1.6) 6.2 (1.6)
Hypertension % 40 33 38
Diabetes mellitus % 6 10 7
Cardiovascular disease % 8 6 7
Smoking % 8 3 5
Lipid lowering drug therapy % 15 25 19
Data are presented as mean values and standard deviations (SD) or
proportions, as appropriate. Hypertension was defined as a blood pressure of
140/90 mm Hg or above, or on-going treatment with anti-hypertensive drugs.
Patients who had an on-going pharmacological treatment for diabetes were
cathegorised as having diabetes mellitus. Cardiovascular disease was defined
as angina pectoris, myocardial infarction, heart failure, atrial fibrillation,
and stroke.
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thirds of a PPS population [5]. Thus, this could be a
background and promote the development of athero-
sclerotic disease including ischemic stroke [5-7]. In con-
trast, however, a Norwegian study among people with
previous poliomyelitis showed no increase in cardiovas-
cular disease [8].
Increased levels of inflammatory markers in cerebro-
spinal fluid and in peripheral blood have been reported
in PPS patients, and have led to the hypothesis of an on-
going inflammatory process [9,10]. Inflammation plays a
key role in the atherosclerotic process, and elevated cir-
culating markers of inflammation have been associated
with an increased cardiovascular risk [11,12]. In chronic
conditions with systemic inflammation, such as systemic
lupus erythematosus and rheumatoid arthritis, altered
metabolism of lipoproteins gives rise to changes in the
lipid profile [13-15]. Even if PPS does not have the clin-
ical hallmarks of a systemic inflammation, the hyperlip-
idaemia earlier described may be secondary to systemic
inflammatory process. The proposed hyperlipidaemia
has led to the suggestion that PPS patients should be
treated generously with lipid lowering drugs. However,
statins may give side effects as myalgia and muscular
weakness, and less frequently rhabdomyolysis, which
may be devastating for PPS patients regarding function
and their ability to participate in designated rehabilita-
tion programmes [16,17].
With this background, the present study was under-
taken in order to evaluate whether dyslipidaemia is
common in PPS patients and if so, if it is correlated to
inflammatory markers. Furthermore, we attempted to
estimate the risk of future coronary heart disease in PPS
patients by means of the Framingham risk score [18].
Methods
We recruited 89 consecutive patients (53 women and
36 men, mean age 65 ± 9 years) from the Post-Polio
Outpatient Clinic at the Department of Rehabilitation
Medicine, Danderyd University Hospital, Stockholm,
Sweden. Patients were included on the basis of PPS diagno-
sis, based on the criteria given by March of Dimes, includ-
ing neurophysiological examination. Exclusion criteria were
patients who were unable to understand verbal or written
instructions. Patient characteristics are presented in Table 1.
Information on the patients was obtained both by question-
naire and from their medical files. In all, 17 patients were
on lipid lowering medication (simvastatin 10-40 mg od
or atorvastatin 10-40 mg od). All patients gave their in-
formed consent according to the declaration of Helsinki,
and the Regional Ethical Review Board, Stockholm, ap-
proved of the study.
Blood samples were collected in the morning after over-
night fasting. Total cholesterol, high density lipoproteincholesterol (HDL), and triglycerides, were analysed in
serum, and low density lipoprotein cholesterol (LDL) was
calculated by Friedewald’s formula [19]. The ratio between
HDL and LDL (HDL/LDL) was calculated as it is com-
monly considered a marker of cardiovascular risk.
Hyperlipidaemia was defined as total cholesterol of >4.9
mmol/L, or LDL >3.0 mmol/L, or on-going treatment
with lipid lowering drugs. C-reactive protein, erythrocyte
sedimentation rate, and leukocyte count were measured
as markers of inflammation, in addition to creatinine and
HbA1c. All the samples were analysed by standard tech-
niques at accredited regional laboratories.
Lipid data were compared to reference values provided
by two earlier published studies. The Nordic Reference
Interval Project (NORIP) is based on blood samples from
3036 healthy individuals in the Nordic countries and pro-
vides reference data for total cholesterol, LDL, HDL, and
triglycerides [20]. Jungner et al. reported on a Swedish
population sample of 147576 males and females obtained
from general health screening, with no information on the
use of medication, and provides results for total choles-
terol and triglycerides [21]. The results of our patients
were matched for age and gender. In the study by Jungner
et al., patients were divided into age categories of 10-year
intervals, and divided into male and female, giving us the
opportunity to match our patients to this. In the NORIP
study the patients were divided into age categories of 18-
29, 30-49 and ≥50, when the authors concluded that this
was necessary (i.e. LDL and total cholesterol), and into
male and female, allowing us to match our patients to this.
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ated data for all 89 PPS patients and for the 72 PPS pa-
tients who did not receive lipid lowering drugs. When the
Jungner et al. study was used as reference, all 89 PPS pa-
tients were included, since that study did not exclude sub-
jects on medication.
In 64 patients (41 women, mean age 64 ± 8 years, and
23 men, mean age 64 ± 10 years) with no known coron-
ary heart disease and no therapy for high blood choles-
terol the Framingham risk score was used to calculate
the 10 year risk of developing an acute myocardial infarc-
tion and/or coronary death [18]. In 5 patients sufficient
background data could not be obtained, and 3 patients
were too old for the Framingham risk algorithm. This risk
algorithm is based on age, gender, total cholesterol or
LDL, HDL, blood pressure, diabetes mellitus, and smoking
in adults more than 30 years old, with no known coronary
heart disease.
Statistics
Data are presented as mean values and standard devia-
tions (SD). Statistical analyses were performed by the
Student’s t-test, and linear regression analyses were
assessed by Pearson’s correlation coefficient. A probabil-
ity (p) <0.05 was considered statistically significant.
Results
Age and smoking habits, as well as laboratory parame-
ters and concomitant disorders are presented in Table 1.
A minority of the patients were smoking. A history of
cardiovascular disease (i.e. angina pectoris, myocardial
infarction, heart failure, atrial fibrillation and stroke) was
present in 7% of the patients. Hypertension was found inTable 2 Lipid values in the PPS patients and two reference po
Patients without lipid lowering dr
PPS NORIP p
Total cholesterol, mmol/L, all patients 5.9(1.0) 5.9 0.8
Total cholesterol, female 6.1(0.9) 5.9 0.07
Total cholesterol, male 5.5(0.9) 5.9 0.04
LDL, mmol/L, all patients 3.8(0.9) 3.6 0.10
LDL, female 4.0(0.9) 3.6 0.03
LDL, male 3.6(0.8) 3.6 0.8
HDL, mmol/L, all patients 1.5(0.4) 1.7 0.001
HDL, female 1.6(0.4) 1.8 0.01
HDL, male 1.3(0.4) 1.5 0.02
Triglycerides, mmol/L, all patients 1.3(0.6) 1.5 0.003
Triglycerides, female 1.2(0.6) 1.5 0.03
Triglycerides, male 1.4(0.7) 1.5 0.3
Total cholesterol, low density lipoprotein cholesterol (LDL), high density lipoprotein
patients without lipid lowering medication, as compared to age and gender match
value and standard deviation (SD).38% of the patients, and the mean systolic blood pres-
sure was normal but in the higher range. C-reactive pro-
tein and leukocyte count were normal, indicating that
there was no on-going inflammation.
Serum lipid values are given in Table 2. Out of the 89
patients, 66 had hyperlipidemia following the definition,
presented above (see Methods). However, compared to
the reference populations, dyslipidaemia was less com-
mon in the PPS group. When analysing mean values,
total cholesterol was lower in the PPS group than in the
study by Jungner et al., but similar to the findings in
NORIP. LDL levels were not different between the pop-
ulations, whereas, HDL was lower in the PPS group than
in NORIP. The PPS population had a LDL/HDL ratio of
2.6 (SD 0.9), as compared to a significantly lower ratio
of 2.2 (SD 0.2) in NORIP (p = 0.03). In the PPS patients
with no lipid lowering medication, the LDL/HDL ratio
was 2.7 (SD 0.9). In the patients with medication for
high blood lipids, the LDL/HDL ratio was 2.4 (SD 0.7).
Triglyceride levels were lower in the PPS group than in
the two reference populations.
There were no relations (all r2 values <0.03) between
inflammatory markers (C-reactive protein, or sedimenta-
tion rate, or leukocyte count) and blood lipids (total
cholesterol, LDL, HDL, or triglycerides).
The Framingham risk score calculated for the PPS pa-
tients, gave a 10-year mean risk of 8% for a coronary ar-
tery disease event.
Discussion
The present study shows that patients with PPS have
normal or lower total cholesterol values than healthy ref-
erence populations, matched for age and sex [20,21].pulations
ugs All patients
PPS Jungner et al p PPS NORIP p
5.7(1.0) 6.4 <0.001 5.7(1.0) 5.9 0.09
6.0(1.0) 6.5 0.001 6.0(1.0) 5.9 0.7
5.3(0.9) 6.1 <0.001 5.3(0.9) 5.9 0.001
- - - 3.6(0.9) 3.6 0.9
- - - 3.8(1.0) 3.6 0.4
- - - 3.4(0.8) 3.6 0.1
- - - 1.5(0.4) 1.7 <0.001
- - - 1.6(0.4) 1.8 <0.001
- - - 1.3(0.4) 1.5 0.003
1.4(0.7) 1.6 0.05 1.4(0.7) 1.5 0.05
1.4(0.8) 1.5 0.5 1.4(0.8) 1.5 0.2
1.4(0.6) 1.7 0.007 1.4(0.6) 1.5 0.1
cholesterol (HDL), and triglyceride levels in all 89 PPS patients and in 72 PPS
ed reference mean values, from NORIP and the study by Jungner et al. Mean
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the reference population. Hence, our results do not cor-
roborate earlier findings of elevated total cholesterol
levels in PPS patients [5,6]. HDL values were, however
lower in patients with PPS, and the LDL/HDL ratio ac-
cordingly increased. In contrast to earlier findings [5,6]
our results do not suggest that abnormal blood lipid
values are common in PPS patients.
High triglyceride values are a common finding in pa-
tients with impaired glucose control. However, we ob-
served lower triglyceride levels in the PPS group than in
the reference populations. Furthermore, 7% of the PPS
group had diabetes mellitus. This is comparable to sub-
jects of similar age and sex in the same geographic re-
gion, as 7% of women and 10% of men aged 65 years in
Stockholm were recently reported to have diabetes [22].
This suggests that patients with PPS do not have an in-
creased prevalence of glucose homeostatic abnormalities.
Only few (7%) of the PPS patients had a history of
cardiovascular disease (which included angina pectoris,
myocardial infarction, heart failure, atrial fibrillation
and stroke). For comparison, in patients of similar age
(65 years) the prevalence of coronary heart disease
in Denmark was reported at 9% [23], heart failure in
Sweden at 2% [24], diagnosed atrial fibrillation in
Sweden 4% [25], and stroke in Norway at 1% [26]. The
risk of dying from heart disease each year in Sweden is
about 200 per 100 000 inhabitants in women and 350
per 100 000 inhabitants in men [27]. Furthermore, the
calculated Framingham risk score in the PPS group
suggests an 8% 10 year risk for future coronary artery
disease event. A 9-11% risk is considered low risk and
21-25% corresponds to normal risk according to the
Framingham risk score [18]. Notwithstanding that we
observed lower HDL in the PPS group, and low HDL is
associated with an increased risk for cardiovascular
events, HDL is actually included in the Framingham
risk score. Taken together our findings are in agree-
ment with results based on PPS patients and their sib-
lings, presented by Farbu and collaborators [8], which
suggest that PPS patients have a low prevalence of car-
diovascular events. Regular contacts with Post-polio
out-patient clinics could be beneficial for early diagno-
ses and may lead to reduction of risk factors.
We found no relation between markers of inflamma-
tion and lipid levels in patients with PPS. Our findings
do not suggest that the inflammatory process in PPS will
cause elevated lipid levels. In other chronic disorders
with systemic inflammation, hyperlipidaemia is present
[13-15]. In PPS signs of inflammation have been reported
in peripheral blood, and in blood vessels of muscle tissue,
which may be an indication of a systemic inflammation.
However, PPS does not show other signs of cronic
inflammation, as seen in for example systemic lupuserythematosus and rheumatoid arthritis. With the present
results one may conclude that the inflammation in PPS
has another background than the one producing hyperlip-
idaemia in chronic rheumatological diseases.
Our results provide no support for a generous ap-
proach in offering PPS patients treatment with statins.
We suggest that statin treatment should be offered to
PPS patients based on the same judgement as for other
subjects. This may be particularly relevant in the rehabili-
tation of PPS patients, as statins have common side effects
from skeletal muscle.
Some potential limitations of this study should be consid-
ered. First, low or normal cholesterol values and low trigly-
ceride values may at first seem surprising, considering the
physical disabilities and, thus, an assumed low physical ac-
tivity of PPS patients. However, PPS patients use more en-
ergy for moving around than a normal population, making
PPS patients actually more fit than might be expected [28].
This could, at least in part, contribute to our findings. Sec-
ond, one may argue that the study population is not repre-
sentative for PPS patients in general. However, our study
population of consecutive patients is large, and PPS patients
of all ages and with different degrees of disability attend our
institution. When evaluating the patients also regarding
age, gender, ethnicity and health status, we believe that the
patients included in the study are representative. Third, the
Framingham risk score could only be calculated for the
PPS patients without concomitant coronary heart dis-
ease, which might give the impression of a lower risk for
the PPS population, than they actually have. However,
most PPS patients were free of cardiovascular disease
and the prevalence of cardiovascular disorders appeared
lower than in the general population suggesting that the
possible confounding influence was limited.
Fourth, in previous studies cytokines were assessed as
inflammatory markers. In the present study in clinical
setting cytokine measurements were not available. Since
blood lipid values in the PPS group were normal, we do
not think that cytokine measurement would change the
conclusion of the present study.
Finally in this study, we were not able to match the pa-
tients for exactly the same age as the controls. However,
the lipid values in the reference material were presented
in different age groups, giving us the opportunity to have
a fair match of patients and controls.
Conclusion
We found low or normal levels of total cholesterol, LDL,
and HDL among PPS patients in Sweden. The inflam-
matory process in PPS does not seem to be associated
with increased lipids values, and PPS does not confer an
increased risk for cardiovascular disease. Thus, statin
treatment should be offered to PPS patients on the same
indication as in other subjects.
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